Future Market Insights (FMI), a leading provider of market intelligence and consulting services, today released its comprehensive report on European Union market for glucose monitoring devices is on the cusp of transformative growth, projected to expand from USD 5.0 billion in 2025 to USD 10.0 billion by 2035, according to a comprehensive new analysis by Future Market Insights (FMI). This near-doubling of market value represents a compound annual growth rate (CAGR) of 7.2%, underscoring the region's accelerating shift toward advanced, patient-centered diabetes management solutions amid escalating public health challenges.

As diabetes prevalence continues to rise across European populations—fueled by aging demographics, lifestyle changes, and increasing rates of obesity—the demand for reliable, innovative glucose monitoring technologies has never been greater. FMI's latest report highlights how this growth trajectory positions the EU as a global leader in integrating digital health tools into routine diabetes care, empowering patients and healthcare providers alike with real-time insights for better outcomes.

Read Full Report-https://www.futuremarketinsights.com/reports/demand-for-glucose-monitoring-devices-in-eu

"The EU's glucose monitoring landscape is evolving rapidly from traditional testing to sophisticated, connected ecosystems," notes the FMI report. Key drivers include the widespread adoption of continuous glucose monitoring (CGM) systems, expanding reimbursement policies across member states, and a growing emphasis on preventive healthcare. These factors are complemented by robust digital health infrastructure investments and a cultural shift toward self-management, enabling patients to take proactive control of their condition.

In 2025, self-monitoring blood glucose (SMBG) devices—encompassing blood glucose meters, testing strips, and lancets—command a dominant 57.9% market share, valued for their accessibility, cost-effectiveness, and established role in daily diabetes management. However, the report forecasts significant momentum in CGM technologies, including sensors, transmitters, and receivers, as patients and clinicians increasingly prioritize accuracy, connectivity, and minimal invasiveness.

By indication, Type II diabetes accounts for 72.4% of the market in 2025, reflecting its overwhelming prevalence in adult-onset, metabolic syndrome, and lifestyle-related cases. This segment drives innovation tailored to complex glycemic control needs, while Type I and gestational diabetes applications also contribute to diversified demand.

Geographically, Western and Central Europe lead the charge. Germany holds the largest share at 28.0% in 2025, supported by mature healthcare systems and high adoption rates, followed by France (22.0%), Italy (18.0%), Spain (12.0%), and the Netherlands (8.0%). Emerging growth in the Rest of Europe, including Nordic and Eastern EU nations, is poised for the highest CAGR at 7.8%, driven by expanding infrastructure and rising awareness.

Industry leaders are at the forefront of this expansion. Companies such as Abbott Laboratories, with its flagship FreeStyle Libre CGM platform, Dexcom Inc., Roche (Accu-Chek), Medtronic, LifeScan, Ascensia Diabetes Care, Senseonics, AgaMatrix, and Ypsomed are investing heavily in next-generation advancements. Trends spotlight the integration of artificial intelligence for predictive analytics, hypoglycemia alerts, and personalized treatment algorithms, alongside enhanced user interfaces that align with EU accessibility standards.

"European healthcare is embracing a fundamental paradigm shift: from reactive to predictive and personalized diabetes care," the report emphasizes. Opportunities abound in AI-powered analytics, smartphone integration, and patient education programs, further accelerated by partnerships with advocacy groups and reimbursement expansions.

Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates: https://www.futuremarketinsights.com/reports/brochure/rep-gb-27190

Request for Discount: https://www.futuremarketinsights.com/reports/sample/rep-gb-27190

Despite challenges like high upfront costs, varying regulatory landscapes, and reimbursement inconsistencies across jurisdictions, the market's resilience is evident. From 2025 to 2030, growth will be shaped by heightened CGM awareness and Eastern European infrastructure development, adding USD 1.7 billion. The subsequent 2030-2035 period is expected to contribute USD 3.3 billion, propelled by widespread adoption of AI-enhanced, next-generation devices.

This robust outlook signals strategic imperatives for stakeholders: manufacturers must prioritize clinical validation, user-centric design, and seamless digital integration to capture premium segments. Healthcare systems, meanwhile, stand to benefit from reduced long-term complications through empowered patient monitoring.

Future Market Insights' in-depth analysis provides decision-makers with actionable intelligence on segments, competitive dynamics, and emerging trends, equipping industry leaders to navigate this high-growth era effectively.

Explore More Related Studies Published by FMI Research:

Canine Cancer Screening Services Market- https://www.futuremarketinsights.com/reports/canine-cancer-screening-services-market

Emergency Backpack Market- https://www.futuremarketinsights.com/reports/emergency-backpack-market

Digital Pathology Displays Market- https://www.futuremarketinsights.com/reports/digital-pathology-displays-market

Demand for Plasma Dynamic Air Sterilizers in UK- https://www.futuremarketinsights.com/reports/demand-for-plasma-dynamic-air-sterilizers-in-uk

Demand for IVC Host in USA- https://www.futuremarketinsights.com/reports/demand-for-ivc-host-in-usa

About Future Market Insights (FMI)

 Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Contact Us:    

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@futuremarketinsights.com